News stories about Scynexis (NASDAQ:SCYX) have been trending somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Scynexis earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.7469468521266 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:
Separately, ValuEngine upgraded Scynexis from a “strong sell” rating to a “sell” rating in a research report on Saturday, December 9th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. Scynexis currently has an average rating of “Hold” and an average price target of $7.75.
Shares of SCYX opened at $1.28 on Friday. The company has a current ratio of 4.43, a quick ratio of 4.43 and a debt-to-equity ratio of 0.48. Scynexis has a 1 year low of $1.26 and a 1 year high of $2.93. The stock has a market cap of $63.23, a price-to-earnings ratio of -1.27 and a beta of 0.26.
Scynexis (NASDAQ:SCYX) last issued its earnings results on Tuesday, March 13th. The company reported ($0.27) earnings per share (EPS) for the quarter. Scynexis had a negative return on equity of 85.99% and a negative net margin of 10,383.59%. The company had revenue of $0.06 million for the quarter.
In related news, CEO Marco Taglietti bought 100,000 shares of Scynexis stock in a transaction on Thursday, March 8th. The shares were purchased at an average price of $1.69 per share, for a total transaction of $169,000.00. Following the completion of the acquisition, the chief executive officer now owns 404,000 shares in the company, valued at $682,760. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last 90 days, insiders have acquired 141,500 shares of company stock worth $237,155. Company insiders own 4.00% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another website, it was stolen and reposted in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/07/scynexis-scyx-receives-coverage-optimism-score-of-0-12.html.
SCYNEXIS, Inc, a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections.
Receive News & Ratings for Scynexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scynexis and related companies with MarketBeat.com's FREE daily email newsletter.